Usami Eiseki, Kimura Michio, Matsuoka Tomoko, Okada Kazutomo, Nakao Toshiya, Yoshimura Tomoaki, Yasuda Tadashi
Dept. of Pharmacy, Ogaki Municipal Hospital.
Gan To Kagaku Ryoho. 2011 Feb;38(2):243-7.
The chemotherapy treatment of non-Hodgkin's lymphoma(NHL)is associated with an increased risk of infection because of the intensity of the treatment. We examined the frequency of herpes zoster infections in 170 non-Hodgkin's lymphoma patients who had completed a chemotherapy course. Furthermore, we examined the risk factors contributing to these infections. This study took place in the Department of Hematology at Ogaki Municipal Hospital. Of the 170 patients treated in our facility, 25 developed herpes zoster(14. 7%), 19 of whom developed symptoms within 30 days of starting the chemotherapy treatment. Significant risk factors for the development of herpes zoster were post-autologous peripheral blood stem cell transplantation, relapsing patients, ten or more total treatments and the use of two or more regimens. In these cases the average interval of the treatments had to be extended from 6. 6 days to 14. 2 days due to the infection(comparing post - infection to pre-infection). We recommend the prophylactic use of low-dose acyclovir in patients with a higher risk of herpes zoster infection. We also recommend further monitoring of other opportunistic infections associated with chemotherapy usage.
非霍奇金淋巴瘤（NHL）的化疗因治疗强度而导致感染风险增加。我们调查了170名完成化疗疗程的非霍奇金淋巴瘤患者中带状疱疹感染的发生率。此外，我们还研究了导致这些感染的危险因素。本研究在大垣市立医院血液科进行。在我们机构接受治疗的170名患者中，25人患上了带状疱疹（14.7%），其中19人在开始化疗治疗后的30天内出现症状。带状疱疹发生的显著危险因素包括自体外周血干细胞移植后、复发患者、总共接受十次或更多次治疗以及使用两种或更多种治疗方案。在这些病例中，由于感染，治疗的平均间隔时间不得不从6.6天延长至14.2天（感染后与感染前相比）。我们建议对带状疱疹感染风险较高的患者预防性使用低剂量阿昔洛韦。我们还建议进一步监测与化疗使用相关的其他机会性感染。
